Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARISOPRODOL vs BRIXADI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
FDA-approved for the treatment of opioid use disorder (opioid dependence) as part of a comprehensive treatment plan
250-350 mg orally 3 times daily and at bedtime
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Primarily metabolized by CYP3A4 to norbuprenorphine (active metabolite) via N-dealkylation; also undergoes glucuronidation.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
Approximately 99% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Volume of distribution is very large, approximately 500–1000 L (about 5–10 L/kg in a 70 kg individual), indicating extensive tissue binding and sequestration.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
Intramuscular injection: bioavailability is nearly 100% due to limited first-pass metabolism; oral bioavailability is <5% due to extensive first-pass metabolism.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease, use with caution and consider dose reduction due to potential accumulation; specific dosing guidelines not established.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A (mild): No adjustment. Child-Pugh Class B (moderate): Start at lower dose and titrate cautiously; maximum recommended weekly dose 16 mg, monthly dose 96 mg. Child-Pugh Class C (severe): Not recommended due to lack of data.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Not approved for use in pediatric patients; safety and efficacy not established.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
No specific dose adjustments recommended; geriatric patients may have increased sensitivity and should be monitored closely for sedation, respiratory depression, and QTc prolongation. Initiate at lower end of dosing range if severe renal or hepatic impairment present.
None
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of harm or death from accidental ingestion; concomitant use of benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
May cause respiratory depression; risk of abuse potential; need to monitor for hepatic dysfunction; adrenal insufficiency; QT prolongation; precipitation of withdrawal if initiated too soon after full agonist opioids; impairment of mental/physical abilities.
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
No specific food interactions are reported for BRIXADI. However, patients should avoid alcohol and grapefruit juice as they may potentiate CNS depression or alter metabolism (grapefruit inhibits CYP3A4, which metabolizes buprenorphine, potentially increasing levels). Advise a balanced diet without restrictions beyond general health recommendations.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
Unknown if excreted in human milk; no M/P ratio available. Consider risks and benefits; avoid breastfeeding if possible.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
No standard dose adjustment; increased clearance in pregnancy may require dose titration to effect. Monitor for withdrawal or inadequate response.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
BRIXADI (buprenorphine extended-release) is a monthly subcutaneous depot formulation for opioid use disorder (OUD). Initiate only after patient is stabilized on transmucosal buprenorphine (e.g., 8–24 mg/day for at least 7 days). Do not use in opioid-naive patients due to risk of precipitated withdrawal. Administer subcutaneously in the abdomen; avoid intramuscular or intravenous injection. Monitor injection site for nodules, granulomas, or infection. Concomitant use with benzodiazepines or CNS depressants requires careful monitoring due to additive respiratory depression. Liver function tests should be monitored periodically due to risk of hepatic injury. BRIXADI contains buprenorphine as the free base, not salt; dose strengths (64 mg, 96 mg, 128 mg) are not equivalent to other buprenorphine formulations. Upon discontinuation, patients may experience prolonged withdrawal due to slow release over weeks.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
BRIXADI is a once-monthly injection to treat opioid dependence and must be given by a healthcare provider only.,Do not attempt to self-administer or remove the injection. The medicine is released slowly over one month.,Notify your doctor immediately if you have trouble breathing, excessive drowsiness, or severe dizziness, especially when combined with alcohol or sedatives.,Avoid use of other opioids (prescription or illicit), as serious side effects including coma or death may occur.,Report any signs of liver problems: dark urine, yellowing skin/eyes, persistent nausea, or abdominal pain.,The injection site may become red, swollen, or painful; contact your doctor if these persist or worsen.,Do not stop BRIXADI suddenly; withdrawal symptoms may occur and can be prolonged.,Keep out of reach of children and pets; accidental exposure can be fatal.
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARISOPRODOL vs BRIXADI, answered by our medical review team.
CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. BRIXADI is a Opioid Partial Agonist that works by Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARISOPRODOL and BRIXADI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. The standard adult dose of BRIXADI is: Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARISOPRODOL and BRIXADI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . BRIXADI is classified as Category C. Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.